Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background
Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.4061/2011/798658 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556531176964096 |
|---|---|
| author | Marzia Rigolli Mariantonietta Cicoira Corinna Bergamini Andrea Chiampan Andrea Rossi Corrado Vassanelli |
| author_facet | Marzia Rigolli Mariantonietta Cicoira Corinna Bergamini Andrea Chiampan Andrea Rossi Corrado Vassanelli |
| author_sort | Marzia Rigolli |
| collection | DOAJ |
| description | Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months. Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms was performed. No differences in baseline characteristics were detected among subgroups. ACE II was a significant predictor of improvement of LV end-diastolic and end-systolic volume (𝑃=.003 and 𝑃=.002, respectively) but not of LV ejection fraction (LVEF); β1AR389 GlyGly was related to improvement of LVEF (𝑃=.02) and LV end-systolic volume (𝑃=.01). The predictive value of polymorphisms remained after adjustment for other clinically significant predictors (𝑃<.05 for all). Conclusions. ACE I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF patients under optimal treatment. |
| format | Article |
| id | doaj-art-0feb35d660254af3a9ce68968c29d554 |
| institution | Kabale University |
| issn | 2090-0597 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-0feb35d660254af3a9ce68968c29d5542025-02-03T05:45:10ZengWileyCardiology Research and Practice2090-05972011-01-01201110.4061/2011/798658798658Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic BackgroundMarzia Rigolli0Mariantonietta Cicoira1Corinna Bergamini2Andrea Chiampan3Andrea Rossi4Corrado Vassanelli5Division of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyDivision of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyDivision of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyDivision of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyDivision of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyDivision of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, ItalyBackground. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months. Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms was performed. No differences in baseline characteristics were detected among subgroups. ACE II was a significant predictor of improvement of LV end-diastolic and end-systolic volume (𝑃=.003 and 𝑃=.002, respectively) but not of LV ejection fraction (LVEF); β1AR389 GlyGly was related to improvement of LVEF (𝑃=.02) and LV end-systolic volume (𝑃=.01). The predictive value of polymorphisms remained after adjustment for other clinically significant predictors (𝑃<.05 for all). Conclusions. ACE I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF patients under optimal treatment.http://dx.doi.org/10.4061/2011/798658 |
| spellingShingle | Marzia Rigolli Mariantonietta Cicoira Corinna Bergamini Andrea Chiampan Andrea Rossi Corrado Vassanelli Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background Cardiology Research and Practice |
| title | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
| title_full | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
| title_fullStr | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
| title_full_unstemmed | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
| title_short | Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background |
| title_sort | progression of left ventricular dysfunction and remodelling under optimal medical therapy in chf patients role of individual genetic background |
| url | http://dx.doi.org/10.4061/2011/798658 |
| work_keys_str_mv | AT marziarigolli progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT mariantoniettacicoira progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT corinnabergamini progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT andreachiampan progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT andrearossi progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground AT corradovassanelli progressionofleftventriculardysfunctionandremodellingunderoptimalmedicaltherapyinchfpatientsroleofindividualgeneticbackground |